" class="no-js "lang="en-US"> Tollys Releases New Preclinical Data Demonstrating Lifelong Potent Anti-tumor Immunity of TL-532 - Medtech Alert
Friday, March 01, 2024

Tollys Releases New Preclinical Data Demonstrating Lifelong Potent Anti-tumor Immunity of TL-532

Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a new generation of synthetic toll-like receptor 3 (TLR3) specific agonist, today announces that it will release the latest preclinical developments of TL-532 at the American Association for Cancer Research (AACR) Annual Meeting 2022.

The preclinical data included in the poster identified TL-532 as the spearhead of a new rationally designed TLR3-agonist family. In monotherapy, it demonstrated substantial tolerance and promising anti-cancer and auto-vaccinal activity, which included unrelated cancers. TL-532 also demonstrated its remarkable ability to overcome Immune Checkpoint Inhibitor (ICI) tumor-resistance, thus increasing the clinical landscape for ICI combination treatment.

Further key highlights from the poster, titled ‘The specific TLR3-agonist TL-532 induces lifelong anti-tumor auto-vaccination, cross-immunity against unrelated cancers and reverses resistance to immune checkpoint inhibitors’:

  • In vivo activity of TL-532 led to substantial tumor growth inhibition (88%) and delay (370%), translating into 35% Complete Response (CR) rate and 5.3-fold median survival benefit
  • Interestingly, among these CRs, 62% (13/21) showed life-long tumor auto-vaccination after three consecutive rechallenges at 3, 10 and 30 months
  • Remarkably, 54% (6/11) of the mice autovaccinated against bladder cancer also demonstrated cross-immunity against an unrelated and poorly immunogenic, syngeneic osteosarcoma cancer cell model (LM8)
  • TL-532 treatment appeared to decrease the expression of the immune checkpoint PD-L1 on tumor cells ex-vivo and in cDCs in vivo and demonstrated a remarkable ability to reverse the anti-PD-L1 tumor-resistance when combined with the ICI leading to doubling of CR rate
  • Ex vivo and in vivo, the tumor cell death by apoptosis induced by TL-532 was associated with a tumor microenvironment switch, evidenced by increases in antitumor biomarker secretion (IFN-α, IFN-λ1, IFN-γ, CCL5, CXCL9, CXCL10, CX3CL10), decreases in protumor biomarkers CCL22 and sFAS, and was associated in vivo with the recruitment and activation of conventional Dendritic Cells (cDCs) and Cytotoxic T-Lymphocytes (CTLs) at the tumor site.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
More On